{
    "organizations": [],
    "uuid": "b59d8fabde5a1c2f0456a59effd1e37f428c40da",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-indias-orchid-pharma-gets-eir-for/brief-indias-orchid-pharma-gets-eir-for-tamil-nadu-facility-idUSFWN1P30ET",
    "ord_in_thread": 0,
    "title": "BRIEF-India's Orchid Pharma Gets EIR For Tamil Nadu Facility",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Orchid Pharma Ltd:\n* GETS EIR FROM U.S. FDA-POST MARKETING ADVERSE DRUG EXPERIENCE REPORTING INSPECTION\n* EIR RECEIVED FOR CO'S TAMIL NADU FACILITY Source text - bit.ly/2CO7kdA Further company coverage:\n ",
    "published": "2018-01-08T17:33:00.000+02:00",
    "crawled": "2018-01-09T17:10:46.010+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "orchid",
        "pharma",
        "ltd",
        "get",
        "eir",
        "marketing",
        "adverse",
        "drug",
        "experience",
        "reporting",
        "inspection",
        "eir",
        "received",
        "co",
        "tamil",
        "nadu",
        "facility",
        "source",
        "text",
        "company",
        "coverage"
    ]
}